People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Adjuvance Technologies Inc. | — | Biotechnology | Series A | $13.4M | $385.3M | 2019 |
Stephen Dilly at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Dilly on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Cheng | 1 | 9 |
| Jeffrey Gardner | 1 | 4 |
| Ken Kelley | 1 | 2 |
| John Gallo | 1 | 2 |
| Gregory Poland | 1 | 1 |
| Govind Ragupathi | 1 | 1 |
| Phil Livingston | 1 | 1 |
| J. Tyler Martin | 1 | 1 |
| Tyler Martin | 1 | 1 |
| Mary Gin | 1 | 1 |
| Christopher Frigon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.